Indian Pharma Dodges U.S. Tariffs | BMW EV Sales Soar in India

To get your dose of daily business news, tune into Mint Top of the Morning on Mint Podcasts available on all audio streaming platforms. https://open.spotify.com/show/7x8Nv1RlOKyMV5IftIJwP1?si=bf5ecbaedd8f4ddc This is Nelson John, and I'll bring you the top business and tech stories, let's get started.  Trump’s Tariffs Shake Global Trade, But India Stays Steady Donald Trump’s sweeping new tariffs—10% on all imports and 27% on Indian goods—sent global markets into a tailspin, yet India’s markets showed resilience. While Japan’s Nikkei plunged nearly 3% and Hong Kong’s Hang Seng fell 1.5%, India’s Sensex and Nifty 50 barely flinched. Analysts say India’s competitive edge remains intact, though foreign investors pulled ₹2,806 crore from stocks. Meanwhile, gold prices surged as investors sought safe havens amid U.S. economic concerns. With central banks increasing gold reserves, the move signals deeper worries about the dollar’s stability. India’s Fuel Trade With the U.S. Faces New Challenges The 27% tariff on Indian imports is set to disrupt India’s $6 billion petroleum trade with the U.S., particularly in refined fuels like gasoline. As Western nations cut Russian oil post-Ukraine war, India became a major supplier—but the new tariff threatens that role. Despite a 3.7% rise in export volume, revenue dropped 7% to $40.4 billion this fiscal year. Private refiners like Reliance and Nayara Energy are expected to take a hit. India is unlikely to retaliate with counter-tariffs, as that would raise domestic crude and LNG prices. Instead, officials are considering boosting imports of U.S. WTI crude to maintain trade ties. India’s Pharma Industry Wins Tariff Exemption Amid Trump’s tariff spree, Indian pharmaceuticals emerged unscathed. The U.S. exempted the sector, recognizing its role in providing affordable medicines worldwide. India supplies 40% of the U.S.’s generic drugs, saving the American healthcare system $219 billion in 2022 alone. With exports worth $8.7 billion to the U.S. and imports of just $800 million, the exemption benefits both nations. However, legal experts warn of potential future scrutiny under Section 232, which assesses imports based on national security concerns. For now, the exemption reinforces India’s status as the “pharmacy of the world,” opening opportunities for biosimilars and domestic API production. BMW India’s EV Sales Soar Despite Industry Caution BMW India defied concerns over slow EV adoption, reporting a threefold surge in electric vehicle sales in Q1 2024. EVs accounted for 17% of its total sales (3,914 units), with overall sales growing 7% year-on-year. While Tata Motors and Maruti Suzuki remain cautious about EV adoption due to infrastructure challenges, BMW sees strong demand even in smaller cities. The company’s latest EV, the BMW iX1 Long Wheelbase, launched at Auto Expo 2024, has already secured 1,500 bookings. However, the auto industry faces headwinds from Trump’s 25% tariff on auto imports, prompting manufacturers to refocus on internal combustion engines (ICE) amid policy uncertainty. Dusit International Returns to India With a Bold Expansion Plan After exiting in 2017, Thailand’s Dusit International is making a comeback in India with plans to sign 30 hotels and 3,000 rooms in three years. “This time, we’re getting it right,” says Siradej Donavanik, VP of Global Hotel Development. The company is targeting tier-II and III cities while maintaining a presence in metros. Led by industry veteran Deepika Arora, Dusit’s expansion includes luxury and upper-midscale brands, with upcoming hotels in Raipur, Bhiwadi, Kolkata, Lonavala, Kasol, and Manali. As India’s luxury travel market surges toward a projected $410 billion by 2030, Dusit sees a prime opportunity to establish a strong foothold. Learn more about your ad choices. Visit megaphone.fm/adchoices